Avalon Pharmaceuticals Announces Special Meeting Date
April 28 2009 - 4:49PM
Business Wire
Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced that
it has scheduled a special meeting of stockholders for Thursday,
May 28, 2009, to consider and vote upon a proposal to adopt an
agreement and plan of merger and reorganization, dated as of
October�27, 2008, as amended, which provides for the acquisition of
Avalon by Clinical Data, Inc (Nasdaq:CLDA). The proposed
acquisition of Avalon by Clinical Data was previously announced on
October 28, 2008.
Avalon stockholders of record at the close of business on April
13, 2009, will be entitled to notice of the special meeting and to
vote on the proposal. The special meeting will begin at 10:00 a.m.,
local time, at Avalon�s offices located at 20358 Seneca Meadows
Parkway, Germantown, Maryland 20876. Avalon expects to mail the
joint definitive proxy statement/prospectus for the special meeting
to its stockholders on or about April 28, 2009.
Avalon expects that the transaction will close as soon as
possible following the special meeting of stockholders, subject to
the adoption of the agreement by Avalon stockholders, as well as
the fulfillment of customary closing conditions.
About Avalon Pharmaceuticals
Avalon is a biopharmaceutical company focused on the discovery,
development and commercialization of first-in-class cancer
therapeutics.
Important Information for Investors and Stockholders
As previously announced, on October 27, 2008 Avalon, Clinical
Data, Inc. and API Acquisition Sub II, LLC, a Delaware corporation
and an indirect wholly-owned subsidiary of Clinical Data, entered
into a definitive Agreement and Plan of Merger and Reorganization
for the acquisition of Avalon by Clinical Data. Avalon and Clinical
Data have filed a joint definitive proxy statement/prospectus with
the Securities and Exchange Commission (�SEC�) in connection with
the proposed merger. The joint definitive proxy statement/
prospectus is expected to be mailed to Avalon stockholders on or
about April 28, 2009. Investors and stockholders are urged to read
the joint definitive proxy statement/prospectus because it contains
important information about the proposed merger.
Investors and stockholders are able to obtain the joint
definitive proxy statement/prospectus and other documents filed
with the SEC free of charge at the website maintained by the SEC at
www.sec.gov. In addition, documents filed with the SEC by Avalon
are available free of charge on the portion of the Avalon website
titled �Investors� at www.avalonrx.com. Documents filed with the
SEC by Clinical Data are available free of charge on the portion of
the Clinical Data website titled �Investors� at www.clda.com.
Clinical Data, Avalon and their directors and executive officers
may be deemed to be participants in the solicitation of proxies
from Avalon stockholders. Information regarding Clinical Data�s
participants is available in Clinical Data�s Annual Report on Form
10-K for the year ended March 31, 2008 and its proxy statement for
its 2008 Annual Meeting of stockholders, which are filed with the
SEC. Information regarding Avalon�s participants is available in
Avalon�s Annual Report on Form 10-K for the year ended December�31,
2008, which is filed with the SEC. Additional information regarding
interests of such participants is included in the joint definitive
proxy statement/prospectus filed with the SEC. You can obtain free
copies of these documents from Clinical Data and Avalon as
indicated above.
Forward Looking Statements
This announcement may contain forward-looking statements that
involve risks and uncertainties. Such statements are based on
certain assumptions and actual results could differ materially from
those currently anticipated as a result of a number of factors,
risks and uncertainties. The information in this Release should be
read in conjunction with the Risk Factors set forth in our 2008
Annual Report on Form 10-K and updates contained in subsequent
filings Avalon makes with the SEC.
Avalon (NASDAQ:AVRX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Avalon (NASDAQ:AVRX)
Historical Stock Chart
From Oct 2023 to Oct 2024